ZARBERA MP TABLET
ZARBERA MP TABLET
Medroxy progesteron 10 mg Tablet
Medroxyprogesterone is a progestin (a form of progesterone), a female hormone that helps regulate ovulation (the release of an egg from an ovary) and menstrual periods. Medroxyprogesterone is used to treat conditions such as absent or irregular menstrual periods, or abnormal uterine bleeding
MECHANISM OF ACTION OF MEDROXY PROGESTERONE 10MG(ZARBERA MP TABLET):
MEDROXYPROGESTERONE IS A SYNTHETIC PROGESTOGEN WHICH CONVERTS THE PROLIFERATIVE PHASE OF THE ENDOMETRIUM INTO SECRETORY PHASE. IT HAS SOME ANDROGENIC AND ANABOLIC ACTIVITIES BUT NO OESTROGENIC EFFECTS. PARENTERAL USE LEADS TO INHIBITION OF PITUITARY GONADOTROPINS, THUS PREVENTING FOLLICULAR MATURATION AND OVULATION. ABSORPTION: WELL ABSORBED FROM THE GIT (ORAL). DISTRIBUTION: ENTERS THE BREAST MILK. PROTEIN-BINDING: HIGHLY BOUND TO ALBUMIN. METABOLISM: HEPATIC. EXCRETION: VIA THE URINE AND FAECES (AS GLUCURONIDE CONJUGATES); ELIMINATION HALF-LIFE: 24-30 HRS (ORAL), 50 DAYS (IM).
SIDE EFFECTS OF MEDROXY PROGESTERONE 10MG(ZARBERA MP TABLET):
DEPRESSION, FLUID RETENTION. FATIGUE, INSOMNIA, DIZZINESS, HEADACHE, NAUSEA; BREAST TENDERNESS; WT GAIN/LOSS, ANOREXIA; CHOLESTATIC JAUNDICE; PAIN AT INJ SITE. POTENTIALLY FATAL: THROMBOPHLEBITIS AND PULMONARY EMBOLISM.
DRUG INTERACTIONS OF MEDROXY PROGESTERONE 10MG(ZARBERA MP TABLET):
AMINOGLUTETHIMIDE AND ENZYME-INDUCING DRUGS (E.G. CARBAMAZEPINE, GRISEOFULVIN, PHENOBARBITAL, RIFAMPICIN, PHENYTOIN) MAY REDUCE PLASMA CONCENTRATIONS LEADING TO REDUCED EFFICACY. ADDITIONAL MEASURES REQUIRED WHEN MEDROXYPROGESTERONE IS USED FOR CONTRACEPTION DURING COADMINISTRATION WITH THESE DRUGS.
CONTRAINDICATIONS OF MEDROXY PROGESTERONE 10MG(ZARBERA MP TABLET):
THROMBOEMBOLIC DISORDERS; CEREBRAL APOPLEXY; SEVERE HEPATIC DYSFUNCTION; UNDIAGNOSED VAGINAL BLEEDING, INCOMPLETE ABORTION, HORMONE-DEPENDENT CARCINOMA; PREGNANCY.
SPECIAL PRECAUTIONS FOR MEDROXY PROGESTERONE 10MG(ZARBERA MP TABLET):
PATIENTS WITH DEPRESSION, DM, EPILEPSY, ASTHMA, MIGRAINE, HYPERTENSION, RENAL OR CARDIAC DYSFUNCTION. MONITOR PATIENT CLOSELY FOR LOSS OF VISION, PROPTOSIS, DIPLOPIA AND THROMBOEMBOLIC DISORDERS. LACTATION.